Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.56 |
| ▸ | MAOA | P21397 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | CALML3 | P27482 | 1/20 | 0.56 |
| ▸ | SDHA | P31040 | 1/20 | 0.56 |
| ▸ | F10 | P00742 | 7/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4150435 | 0.89 | MAOB (0.56) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL13316509 | 0.89 | MAOB (0.58) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL1336215 | 0.89 | MAOB (0.69) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL76846 | 0.89 | MAOB (0.69) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL5513933 | 0.89 | MAOB (0.69) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL29439547 | 0.89 | MAOB (0.69) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL3523989 | 0.89 | F10 (0.59) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL3523994 | 0.89 | F10 (0.59) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL3525075 | 0.87 | F10 (0.58) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL13404010 | 0.87 | F10 (0.58) | MAOBMAOALMNAPTGS1CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796267-B2 | Oxazolidinone derivatives and methods of use | CONCERT PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20130281456-A1 | SYNTHESIS OF DEUTERATED MORPHOLINE DERIVATIVES | LIU JULIE F (US) | 2013-10-24 | — | — | US | disclosed |
| US-8354557-B2 | Synthesis of deuterated morpholine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20100160247-A1 | Synthesis of deuterated morpholine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20090093422-A1 | Oxazolidinone derivatives and methods of use | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2009-04-09 | — | — | US | disclosed |
| US-20090093422-A1 | Oxazolidinone derivatives and methods of use | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093422-A1 | Oxazolidinone derivatives and methods of use | OXA1L, AQP4, AQP3 | MAOB 964/4885MAOA 968/4885LMNA 2912/4885 |
| US-20130281456-A1 | SYNTHESIS OF DEUTERATED MORPHOLINE DERIVATIVES | DRD4, DRD1, DRD2 | MAOB 1448/4885MAOA 2151/4885LMNA 2689/4885 |
| US-20100160247-A1 | Synthesis of deuterated morpholine derivatives | DRD4, DRD1, DRD2 | MAOB 1448/4885MAOA 2151/4885LMNA 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.